- Home
- RYTM vs CHE Comparison
RYTM vs CHE Comparison
Compare RYTM & CHE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RYTM | CHE |
|---|---|---|
| Founded | 2008 | 1970 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Nursing Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.4B | 5.6B |
| IPO Year | 2017 | 1994 |
Fundamental Metrics
Financial Performance| Metric | RYTM | CHE |
|---|---|---|
| Price | $93.06 | $403.81 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 14 | 4 |
| Target Price | $129.43 | ★ $498.00 |
| AVG Volume (30 Days) | ★ 739.0K | 225.1K |
| Earning Date | 01-01-0001 | 06-02-2026 |
| Dividend Yield | N/A | ★ 0.59% |
| EPS Growth | ★ 28.34 | N/A |
| EPS | N/A | ★ 18.34 |
| Revenue | N/A | ★ $2,529,978,000.00 |
| Revenue This Year | $58.38 | $6.60 |
| Revenue Next Year | $83.95 | $6.15 |
| P/E Ratio | ★ N/A | $22.26 |
| Revenue Growth | N/A | ★ 4.06 |
| 52 Week Low | $45.91 | $385.00 |
| 52 Week High | $122.20 | $623.61 |
Technical Indicators
Market Signals| Indicator | RYTM | CHE |
|---|---|---|
| Relative Strength Index (RSI) | 40.55 | 34.79 |
| Support Level | $83.98 | $385.00 |
| Resistance Level | $96.92 | $462.68 |
| Average True Range (ATR) | 4.81 | 13.65 |
| MACD | -0.45 | -6.08 |
| Stochastic Oscillator | 31.11 | 19.00 |
Price Performance
Historical ComparisonAbout RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
About CHE Chemed Corp
Chemed Corp purchases, operates, and divests subsidiaries engaged in diverse business activities to maximize shareholder value. The company operates in the following segments: VITAS and Roto-Rooter. The VITAS segment generates the majority of the firm's revenue and provides hospice and palliative care services to patients with terminal illnesses through a network of physicians, registered nurses, home health aides, social workers, and volunteers. The Roto-Rooter segment provides plumbing, drain cleaning, water restoration, and related services to residential and commercial customers.